.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
Teva
AstraZeneca
Cantor Fitzgerald
Moodys
Fish and Richardson
Harvard Business School
Julphar
US Department of Justice

Generated: December 16, 2017

DrugPatentWatch Database Preview

ONZETRA XSAIL Drug Profile

« Back to Dashboard

When do Onzetra Xsail patents expire, and when can generic versions of Onzetra Xsail launch?

Onzetra Xsail is a drug marketed by Avanir Pharms and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and thirty-three patent family members in twenty-eight countries.

The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-three drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Avanir PharmsONZETRA XSAILsumatriptan succinatePOWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ONZETRA XSAIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,555,878Nasal delivery device► Subscribe
7,347,201Nasal delivery devices► Subscribe
7,481,218Nasal devices► Subscribe
9,522,243Nasal devices► Subscribe
8,596,278Nasal devices► Subscribe
9,144,652Powder delivery devices► Subscribe
9,072,857Nasal delivery device► Subscribe
9,132,249Nasal devices► Subscribe
8,522,778Nasal devices► Subscribe
7,841,337Breath-actuated nasal delivery device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ONZETRA XSAIL

Country Document Number Estimated Expiration
European Patent Office1853338► Subscribe
United Kingdom2408214► Subscribe
New Zealand514442► Subscribe
World Intellectual Property Organization (WIPO)03000310► Subscribe
Australia2002258031► Subscribe
United Kingdom0418931► Subscribe
Australia2002258055► Subscribe
Australia2002255224► Subscribe
Australia2003251088► Subscribe
Austria514445► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Julphar
Queensland Health
Accenture
Johnson and Johnson
AstraZeneca
Fuji
Healthtrust
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot